Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

930 results about "Mucus" patented technology

Mucus (/ˈmjuːkəs/ MEW-kəs) is a polymer. It is a slippery aqueous secretion produced by, and covering, mucous membranes. It is typically produced from cells found in mucous glands, although it may also originate from mixed glands, which contain both serous and mucous cells. It is a viscous colloid containing inorganic salts, antimicrobial enzymes (such as lysozymes), immunoglobulins, and glycoproteins such as lactoferrin and mucins, which are produced by goblet cells in the mucous membranes and submucosal glands. Mucus serves to protect epithelial cells in the linings of the respiratory, digestive, and urogenital systems, and structures in the visual, and auditory systems from pathogenic fungi, bacteria and viruses. Most of the mucus in the body is produced in the gastrointestinal tract.

Lactobacillus mucilaginosus and application thereof

The invention discloses a lactobacillus mucus fermentation strain and application thereof, and provides a lactobacillus mucus fermentation strain A10 with high yield of exopolysaccharides, and the preservation number of the lactobacillus mucus fermentation strain A10 is CCTCC (China Center for Type Culture Collection) NO: M20242082. The fermented lactobacillus mucus A10 has relatively strong bile salt and gastrointestinal tract digestion tolerance and has an obvious antibacterial effect on escherichia coli and staphylococcus aureus, and the exopolysaccharide synthesized by the fermented lactobacillus mucus A10 is Wzy type exopolysaccharide, is heteropolysaccharide composed of rhamnose, galactose, glucose, mannose and glucuronic acid, and can be used for preparing the exopolysaccharide. The product has good thermal stability and antioxidant activity, and can significantly scavenge free radicals. The lactobacillus mucus A10 extracellular polysaccharide provided by the invention can exert antioxidant activity by activating a Keap1-Nrf2 / ARE signal channel, and is expected to be developed into a natural antioxidant which interacts with Keap1-Nrf2 in a targeting manner.
Owner:YUNNAN AGRICULTURAL UNIVERSITY

Limosilactobacillus fermentum VB216 and use thereof

PCT designated stage expiredWO2025021162A1BacteriaDigestive systemBiotechnologyDisease
Provided is a Limosilactobacillus fermentum VB216, which has the deposit number of CGMCC No. 26578 in the China General Microbiological Culture Collection Center, and has the deposit date of 20 February 2023. The Limosilactobacillus fermentum has inhibitory activities with regard to a variety of pathogenic bacteria and excellent activity for degrading arginine. The present invention can be used in the preparation of products, such as food, health-care food, medicine and feed, for preventing and / or relieving and / or treating arginine metabolism-related diseases, such as hyperarginemia, malignant tumor treatment, allergic reactions, eczema, pruritus and abdominal spasm, and has great application prospects.
Owner:HANGZHOU VICROBX BIOTECH CO LTD

Application of lactobacillus mucilaginosus strain A21196 in preparation of product for resisting anxiety and improving memory and concentration

The invention provides an application of a fermentation lactobacillus mucus strain A21196 in preparation of a product for resisting anxiety and improving memory and concentration, and belongs to the technical field of biological medicines. Animal experiments show that the fermented lactobacillus mucus strain A21196 has the effects of resisting anxiety, resisting depression, improving cognitive impairment function and improving memory concentration, and provides a new means for preventing and / or treating nerve diseases related to anxiety disorder, depression and cognitive impairment.
Owner:AIAGE LIFE SCI CORP LTD +1

Probiotic with depression improving effect and microecological preparation and application thereof

The invention discloses a probiotic with the depression improving effect and a microecological preparation and application thereof, and is characterized in that the probiotic comprises lactobacillus mucus PC17 with the preservation number of CGMCC No.33866, the active ingredients of the lactobacillus microecological preparation comprise thalli of the lactobacillus mucus PC17, and a preparation method of the microecological preparation comprises the following steps: adding the lactobacillus mucus PC17 into the lactobacillus mucus PC17, uniformly mixing the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17 and the lactobacillus mucus PC17 The lactic acid bacteria are inoculated into a fermentation culture medium according to a volume ratio of 1-5% to prepare the lactic acid bacteria microecological preparation, can be used for preparing antidepressant drugs, and has the advantages of being capable of promoting RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reducing the levels of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and corticotropin in serum, and improving the antidepressant activity of the antidepressant drugs. The levels of aminobutyric acid and brain-derived neurotrophic factors in serum are improved, and the depression-like behaviors of CUMS depression model mice are obviously improved.
Owner:NINGBO UNIV

Lactobacillus reuteri HNU872 and application thereof in preparation of intestinal inflammation related products

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.
Owner:HAINAN UNIV

Fermented lactobacillus mucus NJ-10 and application thereof in preparation of rare ginsenoside-rich metagen through fermentation conversion

The invention discloses fermented lactobacillus mucus NJ-10 and application thereof in preparation of rare ginsenoside-rich metagen through fermentation conversion, and relates to the field of probiotic fermentation. The lactobacillus fermentum NJ-10 is preserved in the China Center for Type Culture Collection on February 25, 2025, and the preservation number of the lactobacillus fermentum NJ-10 is CCTCC (China Center for Type Culture Collection) NO: M 2025300. According to the present invention, the fermentation lactobacillus mucus NJ-10 capable of producing beta-glucosidase, which is subjected to autonomous separation and identification, can be used for fermentation and conversion of ginseng stem and leaf saponin, and then is subjected to post-generation preparation in a high-temperature and high-pressure steam manner, such that the beta-glucosidase producing beta-glucosidase can be produced, and the beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase can be produced. According to the method, ginseng stem and leaf saponin is converted through two-step fermentation to prepare the postbiotic fermentation product rich in rare ginsenoside, resource utilization of non-medicinal parts of ginseng is expanded, and the postbiotic fermentation product has wide application prospects in the fields of food industry, pharmaceutical industry, cosmetics, animal breeding and the like.
Owner:JILIN AGRICULTURAL UNIV

Lactobacillus mucilaginosus for maintaining genital tract health and preventing genital tract infection and application of lactobacillus mucilaginosus

The invention relates to the technical field of microorganisms, and provides lactobacillus mucilaginosus for maintaining genital tract health and preventing genital tract infection and application of lactobacillus mucilaginosus. Fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection is named as FMTA1113H and is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.34291. The invention further discloses a preparation method of the fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection. According to the technical scheme, the problems that female genital tracts are prone to infection and relapse is prone to occurring after infection in the prior art are solved.
Owner:BEIJING FUMART BIOTECHNOLOGY CO LTD

Dendrobium officinale fermentation liquor with pancreatic lipase inhibition effect and preparation method thereof

The invention belongs to the technical field of traditional Chinese medicine fermentation, and particularly relates to dendrobium officinale fermentation liquor with a pancreatic lipase inhibition effect and a preparation method of the dendrobium officinale fermentation liquor. The dendrobium officinale fermentation liquor is prepared by performing enzymolysis on dendrobium officinale and inoculating lactic acid bacteria for fermentation, wherein the dendrobium officinale fermentation liquor obtained by inoculating fermentation lactobacillus mucus DSM 13273 or leuconostoc mesenteroides subsp. Mesenteroides XD054 has a better pancreatic lipase activity inhibition effect.
Owner:江苏菌钥生命科技发展有限公司 +1

Breast milk-derived limosilactobacillus fermentum MSJK0025 capable of improving intestinal flora condition and use thereof

A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric / intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.
Owner:MINSHENG ZHONGKE JIAYI (ZHEJIANG) BIOENGINEERING CO LTD +1

Probiotics capable of reducing uric acid and product

The invention belongs to the technical field of probiotics and application thereof, and relates to a probiotic capable of reducing uric acid and a product thereof, in particular to a strain of Lentilactobacillusbuchneri strain ZD62 which is preserved in China Center for Type Culture Collection on March 14, 2024, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: M2024469, and the preservation number is CCTCC NO: M2024469, the preservation number is CCTCC NO: M2024469, the preservation number is CCTCC NO: M2024469, and the preservation number is CCTCC NO: M2024469. The invention relates to a compound probiotic agent, which is prepared from Lentilactobacilli buchneri strain ZD62 and Mycobacterium fermentum ZD103, and is characterized in that the Mycobacterium fermentum ZD103 is prepared from Lentilactobacilli buchneri strain ZD62; the lactobacillus buchneri ZD62 and the mucus fermentum ZD103 provided by the invention have a good characteristic of reducing uric acid.
Owner:QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES) +1

Application of Lactobacillus reuteri CCFM1289 with high yield of indoleacetic acid in relieving anxiety and depression

The invention discloses application of Lactobacillus reuteri CCFM1289 with high yield of indoleacetic acid in relieving anxiety and depression, and belongs to the technical field of microorganisms. The Lactobacillus reuteri CCFM1289 can produce heteroauxin at high yield in vivo and in vitro, promote the yield of heteroauxin in fecal flora, relieve anxiety-like and depression-like behaviors of depression mice, relieve HPA hyperfunction, improve the level of brain-derived neurotrophic factor BDNF in hippocampus, promote secretion of 5-HTP and 5-HT in brain, improve the content of heteroauxin in colon, serum and brain, and improve the content of heteroauxin in colon, serum and brain. The compound can be used for improving intestinal flora metabolism imbalance, improving mRNA levels of hippocampal neurogenin-2, synapsin and post-synaptic dense protein 95, maintaining neuronal synaptic function stability, activating AHR signal channels, improving bicortin DCX expression and promoting neurogenesis so as to relieve depression mood, and can be used for drugs, health care products or healthy food for preventing and treating depression.
Owner:JIANGNAN UNIV

Lactobacillus reuteri CCFM1288 for relieving depressive mood and application of lactobacillus reuteri CCFM1288

PendingCN119331766AIncrease alpha-diversitymaintain steady stateMilk preparationNervous disorderSerotoninNervous system
The invention discloses lactobacillus reuteri CCFM1288 for relieving depressive mood and application of the lactobacillus reuteri CCFM1288, and belongs to the technical field of microorganisms. The lactobacillus reuteri CCFM1288 has the tryptophan metabolism capability, and can survive for 7 days in the intestinal tract; after the lactobacillus reuteri CCFM1288 intervenes a depressive mouse, anxiety-like and depression-like behaviors of the mouse can be obviously relieved, flora alpha-diversity is improved, intestinal symbiotic bacteria are promoted to secrete indole substances, intestinal homeostasis is maintained, hypothalamic-pituitary-adrenal axis hyperfunction is relieved, dopamine and serotonin neurotransmitter nervous system functions are improved, and the effect of preventing and treating depression is achieved. The neurotransmitter release is promoted, and the anti-depression effect is achieved. In clinical tests, intervention of Lactobacillus reuteri CCFM1288 can significantly improve the depressive symptom of MDD patients, and a new safe alleviation approach is provided for depression treatment.
Owner:JIANGNAN UNIV

In vitro model of inflamed intestinal barrier

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg / ml and interleukin 8 (IL-8) at a concentration of more than 150 pg / ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg / ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg / ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.
Owner:UNIVERSITE DE FRANCHE COMTE

Lactobacillus mucilaginosus and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder

PendingCN119662448Astrong adhesionHigh content of bioactive substancesBiocideAntibacterial agentsBiotechnologyShigella sp
The invention discloses lactobacillus mucilaginosus and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder. The preservation number of the lactobacillus mucilaginosus is CGMCC (China General Microbiological Culture Collection Center) No.31453. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is not hemolyzed, is sensitive to various common antibiotics and has strong lactic acid production capacity, and fermented supernate of the strain has strong growth inhibition capacity on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae and gardnerella vaginalis and can be used for producing lactic acid. The compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of bioactive substances such as amino acids and derivatives thereof, fatty acids and steroids in fermentation liquor can be greatly increased, the strain has an obvious anti-inflammatory effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in functional food and biological agents, but also opens up a new way for further development of ganoderma spores.
Owner:SICHUAN UNIV

Probiotic composition for preventing and treating anti-tumor treatment associated diarrhea and application thereof

PendingCN119074775AHas self-agglutination/co-agglutinationAntioxidantAntibacterial agentsBacteriaBiotechnologyLactobacillus salivarius
The invention belongs to the technical field of microorganisms. The invention relates to a probiotic composition and application thereof in preparation of products for preventing and / or treating health conditions such as anti-tumor treatment related diarrhea. The probiotic composition comprises the following active ingredients: bifidobacterium bifidum, enterococcus faecalis, lactobacillus salivarius, lactobacillus fermentum mucus and parabacteroides didysonii. The probiotic composition has good safety, self-agglutination capability, oxidation resistance, short-chain fatty acid production capability, in-vitro cell adhesion capability, capability of inhibiting a plurality of pathogenic bacteria, capability of treating anti-tumor treatment related diarrhea and the like.
Owner:SICHUAN ANAEROBIC BIOTECHNOLOGY CO LTD

Lactobacillus reuteri LR69 capable of enhancing gastric mucosal barrier and application, product and method thereof

The invention discloses lactobacillus reuteri LR69 capable of enhancing a gastric mucosal barrier and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus reuteri LR69, and the preservation number of the lactobacillus reuteri LR69 is CGMCC (China General Microbiological Culture Collection Center) No.33731. The lactobacillus reuteri LR69 is a lactobacillus reuteri LR69. The invention also provides application of the strain in preparation of food with an auxiliary protection function on gastric mucosa, and / or food with an intestinal flora regulating function, and / or a product for relieving gastritis, and / or food with an immunity enhancing function, and / or a bacteriostatic agent. The invention further discloses a food with an auxiliary protection function on gastric mucosa, a food with an intestinal flora regulating function, a product for relieving gastritis, a food with an immunity enhancing function, a bacteriostatic agent and an in-vitro bacteriostasis method based on the strain. The lactobacillus reuteri LR69 disclosed by the invention can effectively assist in protecting gastric mucosa, regulating intestinal flora, relieving gastritis, enhancing immunity and realizing broad-spectrum bacteriostasis.
Owner:JIANGSU WECARE BIOTECHNOLOGY CO LTD

Heating apparatus for removing mucus

The heating apparatus for removing mucus comprises a face mask and a chest cover. The face mask may be adapted to be worn adjacent to a face and may retain water between the face mask and the face. The chest cover may be adapted to be worn adjacent to a chest and may retain water between the chest cover and the chest. The face mask and the chest cover may heat when activated and may be adapted to evaporate water to create water vapor which may help to break up mucus located within the user's sinuses and throat. The temperature of the heat created by the face mask and the chest cover may be controlled via a first thermostat control and a second thermostat control, respectively.
Owner:CLARK GARLAND

Eubacterium mucilaginosus E11405 and application thereof

The invention provides Eubacterium mucilaginosus E11405 and an application thereof. The invention provides Eubacterium mucus E11405, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the Eubacterium mucus E11405 is CGMCC No.31231. The invention further provides a preparation method of the Eubacterium mucus E11405. The inventor of the application studies the effect and mechanism of the Eubacterium mucus E11405 in relieving the mouse colorectal cancer, and the result shows that the Eubacterium mucus E11405 has a remarkable relieving effect on the mouse colorectal cancer, and can be used as a probiotic preparation for relieving the colorectal cancer. The Eubacterium mucilaginosus E11405 provides a new strategy for prevention and treatment of colorectal cancer-based digestive tract tumors, has potential clinical application prospects, and is expected to become an effective medicine for treating colorectal cancer-based digestive tract tumors.
Owner:ICDC CHINA CDC

Preparation method of spleen-tonifying and stomach-nourishing nutritional preparation

The invention provides a spleen and stomach conditioning factor lactobacillus reuteri obtained by fermenting poria cocos powder. The strain has good acid resistance, cholate resistance and antibacterial ability. The invention further provides a probiotic preparation which has an obvious effect on improving the spleen and the stomach. In addition, the invention also provides a composite preparation composition containing Lactobacillus reuteri, and the composition effectively promotes normal peristalsis and digestion and absorption functions of gastrointestinal tracts by regulating the secretion level of gastrointestinal hormones, enhances the immunity of the organism, protects intestinal mucosa barriers, comprehensively improves the symptoms of weakness of the spleen and the stomach, and improves the overall health level.
Owner:HUNAN NUTRITION TREE BIOTECHNOLOGY CO LTD

A kind of fermented mucus lactobacillus and its application

The present invention discloses a fermented mucus lactobacillus and its application. The present invention provides a fermented mucus lactobacillus A10 with high extracellular polysaccharide production, and its deposit number is CCTCC NO: M20242082. The fermented mucus lactobacillus A10 has strong bile salt and gastrointestinal digestion tolerance, and has obvious antibacterial effects on Escherichia coli and Staphylococcus aureus. The extracellular polysaccharide synthesized by the fermented mucus lactobacillus A10 is a Wzy type extracellular polysaccharide, which is a heteropolysaccharide composed of rhamnose, galactose, glucose, mannose, and glucuronic acid. It has good thermal stability and antioxidant activity, and can significantly scavenge free radicals. The fermented mucus lactobacillus A10 extracellular polysaccharide provided by the present invention can exert antioxidant activity by activating the Keap1-Nrf2 / ARE signaling pathway, and is expected to be developed into a natural antioxidant that interacts with Keap1-Nrf2 in a targeted manner.
Owner:YUNNAN AGRICULTURAL UNIVERSITY

Yak-derived Lactobacillus reuteri with anti-oxidation, anti-inflammatory and anti-hypoxia capabilities and application of Lactobacillus reuteri

The invention discloses lactobacillus reuteri with antioxidant, anti-inflammatory and anti-hypoxia capabilities, the name of the lactobacillus reuteri is QM11, the classification name of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation date of the lactobacillus reuteri is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing on August 5, 2024, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541. The preservation unit is China General Microbiological Culture Collection Center (CGMCC). The lactobacillus reuteri is separated from faeces of healthy yaks in Qinghai province, has relatively strong acid and cholate tolerance, has relatively good antioxidant and anti-inflammatory capacities, and has a relatively strong inhibition effect on pathogenic bacteria such as yak-derived pathogenic escherichia coli, staphylococcus aureus and salmonella typhimurium; the sodium dextran sulfate induced mouse colitis symptom is relieved, and the hypoxia tolerance of the mouse is improved. The lactobacillus reuteri disclosed by the invention can be used for preparing medicines or microecological preparations for resisting oxidation, inflammation and hypoxia, and has a very wide application prospect.
Owner:TIANJIN UNIV OF SCI & TECH +1

A type of tendon peptide with antioxidant and pancreatic lipase inhibitory activities and its preparation method

This invention relates to the technical field of deep processing of sturgeon by-products, and particularly to a sturgeon tendon peptide with antioxidant and pancreatic lipase inhibitory activities and its preparation method. The preparation method includes the following steps: mixing sturgeon with water and crushing it to form a first slurry; adding Bacillus licheniformis alkaline protease to the first slurry for a first hydrolysis; adding Bacillus subtilis neutral protease to the first hydrolysate for a second hydrolysis; adding a complex enzyme to the second hydrolysate for a third hydrolysis to obtain a sturgeon tendon hydrolysate; filtering the sturgeon tendon hydrolysate to remove impurities to obtain a filtrate, which is then filtered again to retain polypeptides, thus obtaining the sturgeon tendon peptide; wherein the complex enzyme includes pectinase and amylase. Using this method, a sturgeon tendon peptide with high glycosaminoglycan content can be obtained, which exhibits pancreatic lipase inhibitory activity, antioxidant activity, Staphylococcus aureus inhibitory activity, and prebiotic effects that promote the proliferation of Lactobacillus plantarum and Lactobacillus fermentum.
Owner:XIAMEN YUANZHIDAO BIOTECHNOLOGY CO LTD

Application of breast milk-derived plant lactobacillus to improvement of allergic diseases and regulation of intestinal flora

The invention discloses an application of a breast milk-derived plant lactobacillus in improving allergic diseases and regulating intestinal flora, and belongs to the technical field of microorganisms. The plant lactobacillus GDMCC No: 63060 disclosed by the invention is obtained by being separated from breast milk. The strain provided by the invention has excellent gastrointestinal fluid tolerance, mucin adhesion and antibiotic sensitivity, can inhibit various pathogenic bacteria, can generate indole derivatives, effectively inhibits eczema mouse dermatitis symptoms, inhibits Th2 type immunoreaction hyperpolarization, and induces regulatory T cells. Therefore, the lactobacillus plantarum FN029 has a huge application prospect in preparation of products for inhibiting enteropathogenic bacteria, improving allergic diseases, regulating intestinal flora or promoting digestion function.
Owner:SHANGPIN HEALTH TECH (QINGDAO) CO LTD

Bifidobacterium breve capable of removing toxins in body and metagen of bifidobacterium breve

The invention discloses a strain of Bifidobacterium breve capable of removing toxins in a body and a metagen of the Bifidobacterium breve, and belongs to the technical field of microbial application, the Bifidobacterium breve WZA-BB07 is separated from human excrement, and the biological preservation number of the Bifidobacterium breve WZA-BB07 is CCTCC (China Center for Type Culture Collection) NO: M20241530. The bacterial strain WZA-BB07 has a good effect of degrading endotoxin and enterotoxin, the bacterial strain and lactobacillus reuteri are subjected to mixed fermentation to prepare the postbiotics, bifidobacterium breve mainly improves intestinal flora balance and inhibits growth of harmful bacteria, the lactobacillus reuteri helps repair intestinal barriers through metabolites of the lactobacillus reuteri in the fermentation process, and the lactobacillus reuteri and lactobacillus reuteri are mixed to prepare the postbiotics. Metabolism and removal of toxins are enhanced; dendrobium officinale, honeysuckle and radix puerariae extracts are added into a fermentation culture medium, so that rich nutrition is provided for fermentation, the effects of resisting oxidation, resisting inflammation and promoting intestinal repair of medicinal and edible components are also exerted, and the detoxification capacity and the overall health effect of the postbiotic product are further improved.
Owner:胃早安健康科技(山东)有限公司 +1

Application of lactobacillus mucilaginosus TG017 in medicine for preventing and treating hyperuricemia and complications of hyperuricemia

The invention provides a strain of fermentation lactobacillus mucus TG017, and the strain of fermentation lactobacillus mucus TG017 has the effects of reducing uric acid, purine and adenosine. The lactobacillus fermentum is lactobacillus fermentum TG017, is preserved in the China Center for Type Culture Collection on April 10, 2023, has the preservation number of CCTCC NO: M 2023513, and is located in the preservation center of Wuhan University in Hubei China, and the preservation number of the lactobacillus fermentum TG017 is CCTCC NO: M 2023513. The invention further relates to the use of the Lactobacillus mucilaginosus TG017 strain.
Owner:XIAMEN TREATGUT BIOTECHNOLOGY CO LTD

Oral membrane pharmaceutical composition and preparation method thereof

The invention relates to the technical field of oral membranes, in particular to a multilayer oral membrane and a preparation method thereof. The invention provides an oral membrane composition, which comprises semeglutide and pharmaceutically acceptable auxiliary materials, and is characterized in that the composition is formed by combining a drug-containing biological adhesion layer and a backing layer, and the backing layer mainly comprises a membrane forming material, a solvent and a plasticizer; the drug-containing biological adhesion layer mainly comprises semeglutide, a film-forming material, an adhesive, a pH regulator, a flavoring agent and a solvent. By preparing the double-layer oral membrane, the semeglutide is administrated through the oral cavity, and after the insoluble or slowly eroded / dissolved backing layer (preventing saliva from dissolving the medicine) and the adhesive layer containing the main medicine are combined together, the one-way delivery of the main medicine can be realized; through experiments, it is accidentally found that when temperature-sensitive materials such as poloxamer are added to be combined with a conventional adhesive for use, the residence time of the medicine in the oral mucosa can be remarkably prolonged, the curative effect of the medicine is improved, and the main mechanism is that after the medicine is administered, in the oral temperature environment, after the medicine makes contact with mucus on the surface of the oral mucosa, the oral mucosa does not adhere to the oral mucosa. And after the entanglement and piling effects among poloxamer micelles are intensified to form gel, the gel and a conventional adhesive are cooperated to improve the adhesion between the oral membrane and the oral mucosa. Besides, the medicine can be removed at any time, blood sugar can be better controlled, T2DM complications can be better reduced, a more ideal taking mode is provided for weight loss patients, and a new administration mode is provided for reducing blood sugar and reducing weight. The prepared oral cavity membrane is small in size, light in weight, thin, convenient to apply, carry and transport, safe and environmentally friendly to use and capable of meeting the requirements of old people and travelers.
Owner:SHENZHEN JIANXIANG BIOPHARMACEUTICAL CO LTD

Adjustable pharyngeal breather pipe

The invention relates to the technical field of medical breather pipes, in particular to an adjustable pharyngeal breather pipe which comprises a seaming opening, and a through hole is formed in the seaming opening. The gas conduit comprises a main exhaust passage and an oxygen supply interlayer, a sampling gas passage is arranged in the main exhaust passage, and oxygen flows out from an area between the oxygen supply interlayer and the main exhaust passage; the adjusting assembly comprises an impeller; the cleaning mechanism comprises a clamping plug and is used for automatically adjusting the distance between the sampling gas channel and the oxygen outlet according to the oxygen outlet flow, the larger the oxygen flow is, the larger the distance between the sampling gas channel and the oxygen outlet is, and it is avoided that too much oxygen is inhaled to affect the detection result; meanwhile, mucus and water vapor are unblocked through reciprocating movement of the clamping plug, the sampling air channel is guided through the rolling ring, meanwhile, the water vapor of exhaled air is adsorbed, and the mucus and the water vapor are prevented from blocking the air guide pipe.
Owner:SHANGHAI ALIFUN MEDICAL TECH CO LTD +1

Application of lactobacillus mucilaginosus strain A21196 in preparation of product for promoting ethanol metabolism

The invention provides application of a lactobacillus mucus fermentation strain A21196 in preparation of a product for promoting ethanol metabolism, and belongs to the technical field of microbial preparations. The lactobacillus mucus fermentation strain A21196 has the high-yield ethanol dehydrogenase and acetaldehyde dehydrogenase, and has the effects of reducing the content of ethanol and acetaldehyde in the blood of mice suffering from acute alcoholism and shortening the central nervous inhibition time in vivo. Therefore, the invention provides the application of the fermented lactobacillus mucus strain A21196 in preparation of a product for preventing and / or treating the alcoholic liver injury or the alcoholic liver disease.
Owner:AIAGE LIFE SCI CORP LTD

A strain of Bifidobacterium breve capable of clearing toxins in the body and its postbiotics

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.
Owner:胃早安健康科技(山东)有限公司 +1

Fermented lactobacillus mucilaginosus BM01 with bowel relaxing effect and application of fermented lactobacillus mucilaginosus BM01

PendingCN120290408ABacteriaDigestive systemDisease irritable bowelDisease
The invention belongs to the technical field of probiotics, and particularly relates to fermented lactobacillus mucus BM01 with an effect of relaxing bowel and application of the fermented lactobacillus mucus BM01. A new fermented lactobacillus mucus BM01 strain is separated from excrement of a healthy infant in Guangzhou city, Guangdong province, a zebra fish constipation model is constructed through loperamide hydrochloride, and research finds that the strain can remarkably promote intestinal tract movement, increase the content of in-vivo serotonin and inhibit the enzyme activity of dipeptidyl peptidase-4, so that the constipation of the zebra fish can be inhibited, the constipation of the zebra fish can be inhibited, and the constipation of the zebra fish can be inhibited. Therefore, the bowel relaxing effect is achieved. It is indicated that the BM01 strain can play the bowel relaxing effect through multiple mechanisms, has significant application value, can be used for research and development of drugs for treating constipation, irritable bowel syndrome and other intestinal diseases or development of health care products with the bowel relaxing effect, and can also be used as a feed additive to improve animal intestinal health and reduce disease risks. The culture benefit is improved.
Owner:GUANGZHOU HAILILAI FOOD CO LTD +1